The 2024 Japan Convention on Pharmaceutical Ingredients (CPHI Japan) grandly opened on April 17th at the Tokyo Big Sight International Exhibition Center in Japan. This exhibition is Japan's largest professional international pharmaceutical raw materials exhibition, attracting more than 430 exhibitors from around the world, setting a new record for the size of the audience. Nearly ten thousand professionals from the pharmaceutical industry gathered together to participate in this industry event.
Japan is the second-largest pharmaceutical market in Asia and the third largest globally, after the United States and China, accounting for about 7% of the global market share. By participating in this exhibition, we not only gain access to the latest industry trends and technological advancements but also engage in in-depth face-to-face discussions with our clients, reaching cooperation intentions and laying the foundation for further expansion into new markets.
At the exhibition, our factory products such as Sitagliptin intermediates, and Aloe Emodin received significant attention, sparking extensive discussions and further enhancing the products' influence. This also inspires us to continuously innovate and explore more cutting-edge, high-quality pharmaceutical solutions.
We believe that the internationalization process of our company will continue to advance, providing high-quality products and precision services to an increasing number of global customers. We are committed to contributing to the development of the global pharmaceutical industry.
Language